Somatostatin
As of the edition of 20 October 2026, Somatostatin is a protein: marketed, first approved in 1981 (CH); acts on SSTR1, SSTR2 and SSTR3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1993
- Kind
- Protein
- Brand name
- Stilamin
- First approved
- 15 May 1981 (CH)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- EUMEDICA PHARMACEUTICALS (ALLEMAGNE); 2 holders in all
- Registered trials
- 29, 3 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism; Cancer; Hormones; Immune system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 5 | 2 | 1 |
| Phase 1 | 5 | 3 | 1 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 7 | 5 | 0 | 0 |
| Phase 4 | 6 | 3 | 0 | 2 |
| All trials | 29 |